Two biotechnology companies end U.S. IPO lull

Biotechnology companies BeiGene Ltd. and Editas Medicine Inc. priced the first initial public offerings of 2016 in the United States on Tuesday, after over a month without a single successful biotech IPO. This could encourage other companies to proceed with their IPOs.

BeiGene, a Beijing-based company which develops molecules and monoclonal antibodies to treat cancer, priced 6.6 million shares at $24, raising $158.4 million. Editas, a Cambridge, Massachusetts-based company that aims to treat diseases through gene editing, priced 5.9 million shares at $16, raising $94.4 million.

Read the full article at reuters.com…